Q4 2025 IRadimed Corp Earnings Call Transcript
Key Points
- iRadimed Corp (IRMD) achieved its 18th consecutive quarter of record revenue, with Q4 2025 revenue reaching $22.7 million, a 17% increase over Q4 2024.
- The company reported strong growth across all product lines, including a 20% year-over-year increase in MRI-compatible IV infusion pump systems and a 7.5% increase in patient vital signs monitoring systems.
- Gross margins remained robust at approximately 77% for the year and 75% for Q4 2025.
- The new 3870 MRI IV pump is expected to drive significant revenue growth, with anticipated ASP increases of 10% to 14% and a large replacement opportunity.
- iRadimed Corp (IRMD) ended the year with a strong cash position, holding $51.2 million in cash and cash equivalents, and generated $24.9 million in cash flow from operations for the full year.
- The company faces challenges in managing the transition from the 3860 to the 3870 pump, which could impact inventory levels and sales.
- Operating expenses increased to $9.9 million for the quarter and $38.2 million for the full year, reflecting higher general and administrative costs.
- The effective tax rate for the year was 20.7%, which, although lower than the previously estimated 22%, still represents a significant expense.
- The regulatory process for the 3870 pump in Europe and Japan is expected to take time, with CE Mark clearance anticipated by the end of 2026 and Japan clearance not expected until summer 2027.
- The company anticipates a subscale period for gross margins in the first half of 2026, with improvements expected only in the second half as production scales.
Welcome to the IRadimed Corporation Fourth Quarter 2025 Financial Results Conference Call. (Operator Instructions) this call is being recorded today, February 10, 2026, and contains time-sensitive accurate information that is valid only for today.
Earlier, IRadimed released its financial results for the fourth quarter of 2025. A copy of this press release announcing the company's earnings is available under the heading News on the website at iradimed.com.
A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov.
This call is being broadcast live on the company's website at iradimed.com, and a replay will be available there for the next 90 days.
Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans and events and may include the company's expected future results.
IRadimed reminds you that future results may
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
